Skip to main content
Top
Published in: Abdominal Radiology 6/2017

01-06-2017

Assessment of prostate cancer aggressiveness using apparent diffusion coefficient values: impact of patient race and age

Authors: Tsutomu Tamada, Vinay Prabhu, Jianhong Li, James S. Babb, Samir S. Taneja, Andrew B. Rosenkrantz

Published in: Abdominal Radiology | Issue 6/2017

Login to get access

Abstract

Purpose

To assess the impact of patient race and age on the performance of apparent diffusion coefficient (ADC) values for assessment of prostate cancer aggressiveness.

Materials and methods

457 prostate cancer patients who underwent 3T phased-array coil prostate MRI including diffusion-weighted imaging (DWI; maximal b-value 1000 s/mm2) before prostatectomy were included. Mean ADC of a single dominant lesion was measured in each patient, using histopathologic findings from the prostatectomy specimen as reference. In subsets defined by race and age, ADC values were compared between Gleason score (GS) ≤ 3 + 4 and GS ≥ 4 + 3 tumors.

Results

81% of patients were Caucasian, 12% African-American, 7% Asian-American. 13% were <55 years, 42% 55–64 years, 41% 65–74 years, and 4% ≥75 years. 63% were GS ≤ 3 + 4, 37% GS ≥ 4 + 3. ADC was significantly lower in GS ≥ 4 + 3 tumors than in GS ≤ 3 + 4 tumors in the entire cohort, as well as in Caucasian, African-American, and all four age groups (P ≤ 0.015). AUC for differentiation of GS ≤ 3 + 4 and GS ≥ 4 + 3 as well as optimal ADC threshold was Caucasian: 0.73/≤848; African-American: 0.76/≤780; Asian-American: 0.66/≤839: <55 years, 0.73/≤830; 55–64 years, 0.71/≤800; 65–74 years, 0.74/≤872; ≥75 years, 0.79/≤880. A race-optimized ADC threshold resulted in higher specificity in African-American than Caucasian men (84.9% vs. 67.1%, P = 0.045); age-optimized ADC threshold resulted in higher sensitivity in patients aged ≥75 years than <55 years or 55–64 years (100.0% vs. 53.6%–73.3%; P < 0.001).

Conclusion

Patients’ race and age may impact the diagnostic performance and optimal threshold when applying ADC values for evaluation of prostate cancer aggressiveness.
Literature
1.
go back to reference Turkbey B, Mani H, Aras O, et al. (2013) Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology 268:144–152CrossRefPubMedPubMedCentral Turkbey B, Mani H, Aras O, et al. (2013) Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology 268:144–152CrossRefPubMedPubMedCentral
2.
go back to reference Henderson DR, de Souza NM, Thomas K, et al. (2016) Nine-year follow-up for a study of diffusion-weighted magnetic resonance imaging in a prospective prostate cancer active surveillance cohort. Eur Urol 69:1028–1033CrossRefPubMed Henderson DR, de Souza NM, Thomas K, et al. (2016) Nine-year follow-up for a study of diffusion-weighted magnetic resonance imaging in a prospective prostate cancer active surveillance cohort. Eur Urol 69:1028–1033CrossRefPubMed
3.
go back to reference Tamada T, Sone T, Jo Y, Yamamoto A, Ito K (2014) Diffusion weighted magnetic resonance imaging and its role in prostate cancer. NMR Biomed 27:25–38CrossRefPubMed Tamada T, Sone T, Jo Y, Yamamoto A, Ito K (2014) Diffusion weighted magnetic resonance imaging and its role in prostate cancer. NMR Biomed 27:25–38CrossRefPubMed
4.
go back to reference Vos EK, Kobus T, Litjens GJ, et al. (2015) Multiparametric magnetic resonance imaging for discriminating low-grade from high-grade prostate cancer. Invest Radiol 50:490–497CrossRefPubMed Vos EK, Kobus T, Litjens GJ, et al. (2015) Multiparametric magnetic resonance imaging for discriminating low-grade from high-grade prostate cancer. Invest Radiol 50:490–497CrossRefPubMed
5.
go back to reference Donati OF, Mazaheri Y, Afaq A, et al. (2014) Prostate cancer aggressiveness: assessment with whole-lesion histogram analysis of the apparent diffusion coefficient. Radiology 271:143–152CrossRefPubMed Donati OF, Mazaheri Y, Afaq A, et al. (2014) Prostate cancer aggressiveness: assessment with whole-lesion histogram analysis of the apparent diffusion coefficient. Radiology 271:143–152CrossRefPubMed
6.
go back to reference Rosenkrantz AB, Sigmund EE, Johnson G, et al. (2012) Prostate cancer: feasibility and preliminary experience of a diffusional kurtosis model for detection and assessment of aggressiveness of peripheral zone cancer. Radiology 264:126–135CrossRefPubMed Rosenkrantz AB, Sigmund EE, Johnson G, et al. (2012) Prostate cancer: feasibility and preliminary experience of a diffusional kurtosis model for detection and assessment of aggressiveness of peripheral zone cancer. Radiology 264:126–135CrossRefPubMed
7.
go back to reference Bae H, Yoshida S, Matsuoka Y, et al. (2014) Apparent diffusion coefficient value as a biomarker reflecting morphological and biological features of prostate cancer. Int Urol Nephrol 46:555–561CrossRefPubMed Bae H, Yoshida S, Matsuoka Y, et al. (2014) Apparent diffusion coefficient value as a biomarker reflecting morphological and biological features of prostate cancer. Int Urol Nephrol 46:555–561CrossRefPubMed
8.
go back to reference Lebovici A, Sfrangeu SA, Feier D, et al. (2014) Evaluation of the normal-to-diseased apparent diffusion coefficient ratio as an indicator of prostate cancer aggressiveness. BMC Med Imaging 14:15CrossRefPubMedPubMedCentral Lebovici A, Sfrangeu SA, Feier D, et al. (2014) Evaluation of the normal-to-diseased apparent diffusion coefficient ratio as an indicator of prostate cancer aggressiveness. BMC Med Imaging 14:15CrossRefPubMedPubMedCentral
9.
go back to reference Chatterjee A, Watson G, Myint E, et al. (2015) Changes in epithelium, stroma, and lumen space correlate more strongly with gleason pattern and are stronger predictors of prostate adc changes than cellularity metrics. Radiology 277:751–762CrossRefPubMed Chatterjee A, Watson G, Myint E, et al. (2015) Changes in epithelium, stroma, and lumen space correlate more strongly with gleason pattern and are stronger predictors of prostate adc changes than cellularity metrics. Radiology 277:751–762CrossRefPubMed
10.
go back to reference van As NJ, de Souza NM, Riches SF, et al. (2009) A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol 56:981–987CrossRefPubMed van As NJ, de Souza NM, Riches SF, et al. (2009) A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol 56:981–987CrossRefPubMed
11.
go back to reference Rosenkrantz AB, Ream JM, Nolan P, et al. (2015) Prostate cancer: utility of whole-lesion apparent diffusion coefficient metrics for prediction of biochemical recurrence after radical prostatectomy. AJR Am J Roentgenol 205:1208–1214CrossRefPubMedPubMedCentral Rosenkrantz AB, Ream JM, Nolan P, et al. (2015) Prostate cancer: utility of whole-lesion apparent diffusion coefficient metrics for prediction of biochemical recurrence after radical prostatectomy. AJR Am J Roentgenol 205:1208–1214CrossRefPubMedPubMedCentral
12.
go back to reference American Cancer Society (2015) Cancer facts and figures 2015. Atlanta: American Cancer Society American Cancer Society (2015) Cancer facts and figures 2015. Atlanta: American Cancer Society
13.
go back to reference Tsivian M, Bañez LL, Keto CJ, et al. (2013) African-American men with low-grade prostate cancer have higher tumor burdens: results from the Duke Prostate Center. Prostate Cancer Prostatic Dis 16:91–94CrossRefPubMed Tsivian M, Bañez LL, Keto CJ, et al. (2013) African-American men with low-grade prostate cancer have higher tumor burdens: results from the Duke Prostate Center. Prostate Cancer Prostatic Dis 16:91–94CrossRefPubMed
14.
go back to reference Chornokur G, Dalton K, Borysova ME, Kumar NB (2011) Disparities at presentation, diagnosis, treatment, and survival in African-American men, affected by prostate cancer. Prostate 71:985–997CrossRefPubMed Chornokur G, Dalton K, Borysova ME, Kumar NB (2011) Disparities at presentation, diagnosis, treatment, and survival in African-American men, affected by prostate cancer. Prostate 71:985–997CrossRefPubMed
15.
go back to reference Hoffman RM, Gilliland FD, Eley JW, et al. (2001) Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 93:388–395CrossRefPubMed Hoffman RM, Gilliland FD, Eley JW, et al. (2001) Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 93:388–395CrossRefPubMed
16.
go back to reference Oakley-Girvan I, Kolonel LN, Gallagher RP, et al. (2003) Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients. Am J Public Health 93:1753–1759CrossRefPubMedPubMedCentral Oakley-Girvan I, Kolonel LN, Gallagher RP, et al. (2003) Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients. Am J Public Health 93:1753–1759CrossRefPubMedPubMedCentral
17.
go back to reference Chao GF, Krishna N, Aizer AA, et al. (2016) Asian Americans and prostate cancer: a nationwide population-based analysis. Urol Oncol 34:233.e7–233.e15CrossRef Chao GF, Krishna N, Aizer AA, et al. (2016) Asian Americans and prostate cancer: a nationwide population-based analysis. Urol Oncol 34:233.e7–233.e15CrossRef
18.
go back to reference Zhou CK, Check DP, Lortet-Tieulent J, et al. (2016) Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer 138:1388–1400CrossRefPubMed Zhou CK, Check DP, Lortet-Tieulent J, et al. (2016) Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer 138:1388–1400CrossRefPubMed
19.
go back to reference Hall WH, Jani AB, Ryu JK, Narayan S, Vijayakumar S (2005) The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis 8:22–30CrossRefPubMed Hall WH, Jani AB, Ryu JK, Narayan S, Vijayakumar S (2005) The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis 8:22–30CrossRefPubMed
20.
go back to reference Tamada T, Prabhu V, Li J, et al. (2017) Diffusion-weighted MR imaging for detection and assessment of aggressiveness of prostate cancer: comparison between conventional and kurtosis models. Radiology (in press) Tamada T, Prabhu V, Li J, et al. (2017) Diffusion-weighted MR imaging for detection and assessment of aggressiveness of prostate cancer: comparison between conventional and kurtosis models. Radiology (in press)
21.
go back to reference Rosenkrantz AB, Kim S, Campbell N, et al. (2015) Transition zone prostate cancer: revisiting the role of multiparametric MRI at 3 T. AJR Am J Roentgenol 204:W266–W272CrossRefPubMed Rosenkrantz AB, Kim S, Campbell N, et al. (2015) Transition zone prostate cancer: revisiting the role of multiparametric MRI at 3 T. AJR Am J Roentgenol 204:W266–W272CrossRefPubMed
22.
go back to reference Meng X, Rosenkrantz AB, Mendhiratta N, et al. (2016) Relationship between prebiopsy multiparametric magnetic resonance imaging (MRI), biopsy indication, and MRI-ultrasound fusion-targeted prostate biopsy outcomes. Eur Urol 69:512–517CrossRefPubMed Meng X, Rosenkrantz AB, Mendhiratta N, et al. (2016) Relationship between prebiopsy multiparametric magnetic resonance imaging (MRI), biopsy indication, and MRI-ultrasound fusion-targeted prostate biopsy outcomes. Eur Urol 69:512–517CrossRefPubMed
23.
go back to reference Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, ISUP Grading Committee (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29:1228–1242CrossRefPubMed Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, ISUP Grading Committee (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29:1228–1242CrossRefPubMed
24.
go back to reference Klotz L, Zhang L, Lam A, et al. (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131CrossRefPubMed Klotz L, Zhang L, Lam A, et al. (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131CrossRefPubMed
25.
go back to reference Selvadurai ED, SingheraM Thomas K, et al. (2013) Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol 64:981–987CrossRefPubMed Selvadurai ED, SingheraM Thomas K, et al. (2013) Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol 64:981–987CrossRefPubMed
26.
go back to reference Bul M, van den Bergh RC, Zhu X, et al. (2012) Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int 110:1672–1677CrossRefPubMed Bul M, van den Bergh RC, Zhu X, et al. (2012) Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int 110:1672–1677CrossRefPubMed
27.
go back to reference Tamada T, Kanomata N, Sone T, et al. (2014) High b value (2000 s/mm2) diffusion-weighted magnetic resonance imaging in prostate cancer at 3 Tesla: comparison with 1000 s/mm2 for tumor conspicuity and discrimination of aggressiveness. PLoS One 9:e96619CrossRefPubMedPubMedCentral Tamada T, Kanomata N, Sone T, et al. (2014) High b value (2000 s/mm2) diffusion-weighted magnetic resonance imaging in prostate cancer at 3 Tesla: comparison with 1000 s/mm2 for tumor conspicuity and discrimination of aggressiveness. PLoS One 9:e96619CrossRefPubMedPubMedCentral
28.
go back to reference Rozenberg R, Thornhill RE, Flood TA, et al. (2016) Whole-tumor quantitative apparent diffusion coefficient histogram and texture analysis to predict gleason score upgrading in intermediate-risk 3 + 4 = 7 prostate cancer. AJR Am J Roentgenol 206:775–782CrossRefPubMed Rozenberg R, Thornhill RE, Flood TA, et al. (2016) Whole-tumor quantitative apparent diffusion coefficient histogram and texture analysis to predict gleason score upgrading in intermediate-risk 3 + 4 = 7 prostate cancer. AJR Am J Roentgenol 206:775–782CrossRefPubMed
Metadata
Title
Assessment of prostate cancer aggressiveness using apparent diffusion coefficient values: impact of patient race and age
Authors
Tsutomu Tamada
Vinay Prabhu
Jianhong Li
James S. Babb
Samir S. Taneja
Andrew B. Rosenkrantz
Publication date
01-06-2017
Publisher
Springer US
Published in
Abdominal Radiology / Issue 6/2017
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-017-1058-y

Other articles of this Issue 6/2017

Abdominal Radiology 6/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine